In this webinar, Joel Morris, PhD, of the National Cancer Institute (NCI) will introduce a novel therapeutic fluorinated cytidine compound that shows high efficacy against colon cancer and leukemia, producing complete regression in xenograph mouse models (with minimal effects on body weight).
You will learn how this novel compound has superior efficacy over several FDA approved cancer cytidine-based therapeutics (e.g., gemcitabine, azacytidine and decitabine) and why this compound shows promise as a potentially superior therapeutic treatment for colon cancer and leukemia. Among some of the superior aspects of this novel compound are its ability to provide complete and durable tumor regression in study animals beyond post-implant day 150 and its evidence of oral activity, which expands options for route of administration beyond the current FDA approved cytidine-based injectable therapeutics.
* Potential therapeutic for various types of cancers – including colon cancer and leukemia.
* Competitive in vivo efficacy study in several human tumor xenograft studies that indicated low toxicity and high efficacy vs. gemcitabine.
* Produced complete tumor regression in colon cancer mouse models with a durable response beyond 150 days
* Complete tumor regression was observed in a leukemia mouse xenograft model.
* Incorporating fluorine increases lipophilicity through steric and electronic effects.
* Evidence of oral activity expands options for route of administration beyond current FDA approved cytidine-based injectable therapeutics.
* Increased lipophilicity blocks cancer cell metabolism and increases agent potency.
* Increased selectivity and decreased toxicity compared to other aza-cytidines (e.g., gemcitabine, azacytidine and decitabine).
* Assess the prospect of potentially licensing this technology.
* Interact with the inventor, ask questions and provide feedback.
* Learn how to partner with the NCI.
Read more about this new technology: https://pubmed.ncbi.nlm.nih.gov/33811149/